DNA Methylation and Vascular Function
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · May 15, 2018
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "DNA Methylation and Vascular Function," is investigating how changes in DNA, specifically a process called hypomethylation, may lead to increased inflammation and poor blood vessel function in people who are obese. Researchers believe that understanding these changes could help develop non-drug treatments, like aerobic exercise, to improve health in individuals with obesity. The trial is currently recruiting participants.
To be eligible for this study, you must be between 18 and 50 years old, have a body mass index (BMI) of 35 or higher, and be approved for bariatric surgery (a type of weight-loss surgery). It’s important to note that pregnant women and those with certain health conditions, like cancer or heart disease, cannot participate. If you join, you can expect to undergo assessments related to your DNA and vascular health, and learn more about how lifestyle changes like exercise might help your overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI ≥ 35 kg/m2
- • Between ages 18-50 years
- • Not pregnant
- • Approved for a bariatric surgery
- Exclusion Criteria:
- • To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded
- • Pregnant women will be excluded, as they will not be eligible for bariatric surgery
- • Current smokers
- • Currently abusing alcohol or drugs
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Abeer Mohamed, MD, PhD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials